Triazolopyridine compounds and their use as ask inhibitors

Abstract

The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation.

1 . A triazolopyridine compound of formula I: 
       
         
           
           
               
               
           
         
         Formula (I) 
         wherein: 
         R 1  is selected from: 
         a) —NR 6 R 7 ; 
         b) C 3 -C 8 -cycloalkoxy, or C 1 -C 6 -alkoxy; 
         c) C 3 -C 8 -cycloalkyl sulfanyl, or C 1 -C 6 -alkyl sulfanyl; or 
         d) 5 or 6-membered heteroaryl having at least one heteroatom selected from N, S or O, said heteroaryl being substituted with C 1 -C 6  alkyl, halogen, or C 1 -C 6  alkoxy; 
         R 2  is selected from: 
         a) hydrogen; 
         b) halogen; 
         c) aryl that is unsubstituted or is substituted with R 10 , R 11  and/or R 12 ; or 
         d) 5 to 10-membered heteroaryl having at least one heteroatom selected from N, S or O and wherein said 5 to 10-membered heteroaryl is unsubstituted or is substituted with C 1 -C 6  alkyl; 
         or R 1  and R 2  taken together form a —C═C—C═C— group-; 
         R 3  is selected from: 
         a) hydrogen; 
         b) halogen; or 
         c) C 1 -C 6 -alkyl that is unsubstituted or is substituted with at least one fluoro; 
         R 4  is selected from: 
         a) hydrogen; or 
         b) 5 or 6-membered heteroaryl having at least one heteroatom selected from N, S or O; 
         R 5  is selected from: 
         a) C 1 -C 6 -alkyl that is unsubstituted or is substituted with at least one of the following groups:
 i) alkoxycarbonyl, 
 ii) C 1 -C 6 -alkoxy, 
 iii) —NC(O)R′ wherein R′ is an aryl that is unsubstituted or is substituted with C 1 -C 6 -alkyl, or 
 iv) benzyloxy; 
 
         b) aryl-C 1 -C 6 -alkyl; 
         c) 5 or 6-membered heteroaryl-C 1 -C 6 -alkyl having a heteroatom selected from N, S or O that is unsubstituted or is substituted with C 1 -C 6 -alkyl, halogen or C 1 -C 6 -alkoxy; 
         d) C 3 -C 6 -cycloalkyl that is substituted with phenyl; 
         e) 3 to 8-membered heterocycloalkyl having a heteroatom selected from N, S or O that is substituted with an acyl group; 
         f) aryl that is unsubstituted or is substituted with at least one of the following groups:
 i) C 1 -C 6 -alkyl, 
 ii) halogen, 
 iii) C 1 -C 6 -alkoxy, 
 iv) perfluoro-C 1 -C 6 -alkyl, 
 v) at least one C 1 -C 6 -alkoxy that is unsubstituted or is substituted with C 1 -C 6 -alkoxy carbonyl, 
 vi) phenyl, 
 vii) C 1 -C 6 -alkyl sulfonyl, 
 viii) —NHC(O)C 1 -C 6 -alkyl, 
 ix) amino-C 1 -C 6 -alkyl wherein amino is selected from —NH 2 , —NHC 1 -C 6 -alkyl, —N(C 1 -C 6 -alkyl) 2 , N(C 1 -C 6 -alkyl)(C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl), and the two substituents C 1 -C 6 -alkyl can be the same or different, and wherein the two substituents may form a 3 to 8-membered heterocycloalkyl with the N to which they are attached and wherein the heterocycloalkyl is unsubstituted or is substituted with C 1 -C 6 -alkyl or with hydroxy, 
 x) —N(C 1 -C 6 -alkyl) (C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl), 
 xi) 5 to 6-membered heterocycloalkyl-C 1 -C 6 -alkyl having a heteroatom selected from N and O, or 
 xii) amido-C 1 -C 6 -alkyl; 
 
         g) 5 to 10-membered heteroaryl having at least one heteroatom selected from N, O or S optionally substituted with halogen; or 
         h) pyridinyl that is unsubstituted or is substituted with at least one of the following groups:
 i) halogen, 
 ii) C 1 -C 6 -alkyl, 
 iii) amino-C 1 -C 6 -alkyl wherein amino is selected from —NH 2 , —NHC 1 -C 6 -alkyl or —N(C 1 -C 6 -alkyl) 2 , wherein the two substituents C 1 -C 6 -alkyl can be the same or different, and wherein the two substituents may form a 3 to 8-membered heterocycloalkyl with the N to which they are attached and wherein the heterocycloalkyl is unsubstituted or is substituted with C 1 -C 6 -alkyl or hydroxy, 
 iv) —NH(hydroxy-C 1 -C 6 -alkyl), 
 v) —NH-(5-membered heteroaryl-C 1 -C 6 -alkyl having as heteroatom O), 
 vi) 5 or 6-membered heterocycloalkyl-C 1 -C 6 -alkyl having at least one heteroatom selected from O or N, 
 vii) 5 or 6-membered heterocycloalkyl having at least one heteroatom selected from O or N and that is unsubstituted or is substituted with hydroxy, —C(O)OR′ wherein R′ is C 1 -C 6 -alkyl, halogen or C 1 -C 6 -alkyl, 
 viii) amino, 
 ix) —NH(amino-C 1 -C 6 -alkyl), or 
 x) —N(C 1 -C 6 -alkyl) 2 ; 
 
         R 6  is selected from: 
         a) C 1 -C 6 -alkyl that is unsubstituted or is substituted with one or two hydroxy groups; 
         b) phenyl substituted with at least one of the following groups:
 i) halogen, 
 ii) C 1 -C 6 -alkyl, or 
 iii) C 1 -C 6 -alkoxy; 
 
         c) 5 or 6-membered heterocycloalkyl having a heteroatom selected from O or N and substituted with C 1 -C 6 -alkyl; 
         d) C 3 -C 8 -cycloalkyl substituted with R 8 ; or 
         e) —(CH 2 ) n R 9  wherein n equals 1, 2 or 3; 
         R 7  is: 
         a) hydrogen; or 
         b) C 1 -C 6 -alkyl; 
         or R 6  and R 7  can form a 3 to 8-membered heterocycloalkyl with the N to which they are attached and wherein the heterocycloalkyl is substituted with C 1 -C 6 -alkyl; 
         R 8  is selected from: 
         a) hydrogen; 
         b) hydroxy; 
         c) C 1 -C 6 -alkyl that is unsubstituted or is substituted with hydroxy; 
         d) C(O)O—C 1 -C 6 -alkyl; or 
         e) —NH 2 ; 
         R 9  is selected from: 
         a) C 3 -C 8 -cycloalkyl that is unsubstituted or is substituted with an unsubstituted C 1 -C 6 -alkyl; 
         b) 5 or 6-membered heterocycloalkyl having a heteroatom selected from N and O and that is unsubstituted or is substituted with C 1 -C 6 -alkyl; 
         c) 5 or 6-membered heteroaryl having a heteroatom selected from N and O that is unsubstituted or is and that is unsubstituted or is substituted with C 1 -C 6 -alkyl; or 
         d) phenyl; and 
         R 10 , R 11  and R 12  are each independently selected from: 
         a) hydrogen; 
         b) halogen; 
         c) hydroxy; 
         d) C 1 -C 6 -alkyl; 
         e) C 1 -C 6 -alkoxy; 
         f) cyano; 
         g) —C(O)NH(C 1 -C 6 -alkyl)amino wherein the amino is —N(CH 3 ) 2 ); or 
         h) —NH 2 . 
       
     
     
         2 . The triazolopyridine compound according to  claim 1  wherein:
 R 1  is selected from: 
 a) —NR 6 R 7 ; 
 b) C 3 -C 8 -cycloalkoxy; 
 c) C 3 -C 8 -cycloalkyl sulfanyl; or 
 d) 5 or 6-membered heteroaryl having at least one heteroatom selected from N, S or O that is substituted with C 1 -C 6 -alkyl; 
 R 2  is selected from: 
 a) hydrogen; 
 b) Cl or Br; 
 c) aryl that is unsubstituted or is substituted with R 10 , R 11  and/or R 12 ; or 
 d) 5, 6 or 9-membered heteroaryl having at least one heteroatom selected from N, S or O and that is unsubstituted or is substituted with C 1 -C 6  alkyl; 
 or R 1  and R 2  taken together form a —C═C—C═C— group-; 
 R 3  is selected from: 
 a) hydrogen; 
 b) chloro or bromo; 
 c) methyl; or 
 d) CF 3 ; 
 R 4  is selected from: 
 a) hydrogen; or 
 b) furanyl; 
 R 5  is selected from: 
 a) C 1 -C 6 -alkyl that is unsubstituted or is substituted with at least one of the following groups:
 i) alkoxycarbonyl, 
 ii) C 1 -C 6 -alkoxy, 
 iii) —NHC(O)R′ wherein R′ is an aryl that is unsubstituted or is substituted with C 1 -C 6 -alkyl, or 
 iv) benzyloxy; 
 
 b) aryl-C 1 -C 6 -alkyl; 
 c) 5 or 6-membered heteroaryl-C 1 -C 6 -alkyl having a heteroatom selected from N, S or O that is unsubstituted or is and that is unsubstituted or is substituted with C 1 -C 6 -alkyl, halogen or C 1 -C 6 -alkoxy; 
 d) C 3 -C 6  cycloalkyl that is substituted with phenyl; 
 e) 3 to 8-membered heterocycloalkyl having a heteroatom selected from N, S or O and that is unsubstituted or is substituted with an acyl group; 
 f) aryl that is unsubstituted or is substituted with at least one of the following groups:
 i) C 1 -C 6 -alkyl, 
 ii) halogen, 
 iii) C 1 -C 6 -alkoxy, 
 iv) perfluoro-C 1 -C 6 -alkyl, 
 v) at least one C 1 -C 6 -alkoxy that is unsubstituted or is substituted with C 1 -C 6 -alkoxy carbonyl, 
 vi) phenyl, 
 vii) C 1 -C 6 -alkyl sulfonyl, 
 viii) —NC(O)C 1 -C 6 -alkyl, 
 ix) amino-C 1 -C 6 -alkyl wherein amino is selected from —NH 2 , —NHC 1 -C 6 -alkyl, —N(C 1 -C 6 -alkyl) 2 , N(C 1 -C 6 -alkyl)(C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl), and the two substituents C 1 -C 6 -alkyl can be the same or different, and wherein the two substituents may form a 3 to 8-membered heterocycloalkyl with the N to which they are attached and wherein the heterocycloalkyl is unsubstituted or is substituted with C 1 -C 6 -alkyl or with hydroxy, 
 x) —N(C 1 -C 6 -alkyl) (C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl), 
 xi) 5 to 6-membered heterocycloalkyl-C 1 -C 6 -alkyl having a heteroatom selected from N and O, or 
 xii) amido-C 1 -C 6 -alkyl; 
 
 g) 5 to 10-membered heteroaryl having at least one heteroatom selected from N that is unsubstituted or is substituted with halogen; or 
 h) pyridinyl that is unsubstituted or is substituted with at least one of the following groups:
 i) halogen, 
 ii) C 1 -C 6 -alkyl that is unsubstituted or is substituted with a 5 or 6-membered heterocycloalkyl having at least one heteroatom selected from O or N, 
 iii) 5 or 6-membered heterocycloalkyl having at least one heteroatom selected from O or N, 
 iv) —NH(hydroxy-C 1 -C 6 -alkyl), 
 v) —NH-(5-membered heteroaryl-C 1 -C 6 -alkyl having as heteroatom O), 
 vi) 5 or 6-membered heterocycloalkyl-C 1 -C 6 -alkyl having at least one heteroatom selected from O or N, 
 vii) 5 or 6-membered heterocycloalkyl having at least one heteroatom selected from O or N and that is unsubstituted or is substituted with hydroxy, —C(O)OR′ wherein R′ is C 1 -C 6 -alkyl, halogen or C 1 -C 6 -alkyl, 
 viii) amino, 
 ix) —NH(amino-C 1 -C 6 -alkyl), or 
 x) —N(C 1 -C 6 -alkyl) 2 ; 
 
 R 6  is selected from: 
 a) C 1 -C 6 -alkyl that is unsubstituted or is substituted with one or two hydroxy groups, 
 b) phenyl that is unsubstituted or is substituted with at least one of the following groups:
 i) halogen, 
 ii) C 1 -C 6 -alkyl, or 
 iii) C 1 -C 6 -alkoxy; 
 
 c) 5 or 6-membered heterocycloalkyl having a heteroatom selected from O or N and that is unsubstituted or is substituted with C 1 -C 6 -alkyl; 
 d) C 3 -C 8 -cycloalkyl that is unsubstituted or is substituted with R 8 ; or 
 e) —(CH 2 ) n R 9  wherein n equals 1, 2 or 3; 
 R 7  is: 
 a) hydrogen; or 
 b) C 1 -C 6 -alkyl; 
 or R 6  and R 7  can form a 3 to 8-membered heterocycloalkyl with the N to which they are attached and wherein the heterocycloalkyl is unsubstituted or is substituted with C 1 -C 6 -alkyl; 
 R 8  is selected from: 
 a) hydrogen; 
 b) hydroxy; 
 c) unsubstituted or substituted C 1 -C 6 -alkyl wherein the substituent is hydroxyl; 
 d) C(O)O—C 1 -C 6 -alkyl; or 
 e) —NH 2 ; 
 R 9  is selected from: 
 a) C 3 -C 8 -cycloalkyl that is unsubstituted or is substituted with an unsubstituted C 1 -C 6 -alkyl; 
 b) 5 or 6-membered heterocycloalkyl having a heteroatom selected from N and O that is unsubstituted or is substituted with C 1 -C 6 -alkyl; 
 c) 5 or 6-membered heteroaryl having a heteroatom selected from N and O that is unsubstituted or is substituted with C 1 -C 6 -alkyl; or 
 d) phenyl; and 
 R 10 , R 11  and R 12  are each independently selected from: 
 a) hydrogen; 
 b) fluoro or bromo; 
 c) hydroxyl; 
 d) C 1 -C 6 -alkyl; 
 e) C 1 -C 6 -alkoxy; 
 f) cyano; 
 g) —C(O)NH(C 1 -C 6 -alkyl)amino wherein the amino is —N(CH 3 ) 2 ); or 
 h) —NH 2 . 
 
     
     
         3 . A triazolopyridine compound of the following Formula I-6: 
       
         
           
           
               
               
           
         
         Formula I-6 
         wherein: 
         R 4  is furanyl; and 
         R 5  is selected from unsubstituted phenyl; or 5 or 6-membered heteroaryl having a heteroatom selected from N, S or O. 
       
     
     
         4 . The triazolopyridine compound according to  claim 3 , wherein R 5  is a 5-membered heteroaryl having a heteroatom selected from N, S or O. 
     
     
         5 . The triazolopyridine compound according to  claim 3 , wherein R 5  is an unsubstituted phenyl. 
     
     
         6 . A triazolopyridine compound selected from:
 N-[5-(cyclopropylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-(5-pyrrolidin-1-yl[1,2,4]triazolo[1,5-a]pyridin-2-yl)nicotinamide;   N-[1,2,4]triazolo[1,5-a]quinolin-2-ylnicotinamide;   N-[5-(cyclopentylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]benzamide;   N-{5-[(3-methoxypropyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}benzamide;   N-{5-[(2-furylmethyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}benzamide;   N-{5-[(tetrahydrofuran-2-ylmethyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}benzamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]benzamide;   N-(5-{[1-(hydroxymethyl)propyl]amino}[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide;   N-{5-[(2-methoxyethyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}benzamide;   N-{5-[(2,3-dihydroxypropyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}benzamide;   N-[5-(benzylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cycloheptylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide dihydrochloride;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-(5-{[(5-methyl-2-furyl)methyl]amino}[1,2,4]triazolo[1,5-a]pyridin-2-yl)nicotinamide;   N-{5-[(tetrahydrofuran-2-ylmethyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide;   N-[5-(cyclooctylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-{5-[cyclohexyl(methyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide;   N-[5-(tetrahydro-2H-pyran-4-ylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-{5-[(1-methylpiperidin-4-yl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide;   N-{5-[(3-aminocyclohexyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}benzamide;   N-{5-[(1-methylpiperidin-4-yl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}benzamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cyclohexylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cycloheptylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cyclopentylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-[(cyclohexylmethyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-{5-[(3-hydroxycyclohexyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide;   N-{5-[(4-tert-butylcyclohexyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide;   N-[5-(tetrahydro-2H-pyran-3-ylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]benzamide;   N-[5-(cycloheptylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-(morpholin-4-ylmethyl)benzamide;   N-[5-(cyclohexylthio)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-{5-[(trans-4-hydroxycyclohexyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide;   N-[5-(cyclobutylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-morpholin-4-ylnicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-[(dimethylamino)methyl]benzamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-3-(morpholin-4-ylmethyl)benzamide;   N-[5-[(cyclopropylmethyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   methyltrans-4-{[2-[(pyridin-3-ylcarbonyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-5-yl]amino}cyclohexanecarboxylate;   N-[5-{[(1RS,2RS)-2-(hydroxymethyl)cyclohexyl]amino}-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[6-bromo-5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cycloheptylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]tetrahydro-2H-pyran-4-carboxamide;   N-(3-{[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}-3-oxopropyl)benzamide;   N-[5-(isopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(sec-butylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(methylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cyclohexyloxy)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-2-(3-methoxyphenyl)acetamide;   N-[5-(cyclohexyloxy)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-(2-pyrrolidin-1-ylethyl)nicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-(morpholin-4-ylmethyl)nicotinamide;   N-{5-[(cyclohexylmethyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide;   N-{5-[(4-hydroxycyclohexyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}-3-methoxybenz amide;   N-[5-(cyclopentylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-2-furamide;   N-[7-chloro-5-(cyclobutylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[7-chloro-5-(cyclopentylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[7-chloro-5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(sec-butylamino)-7-chloro[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[7-chloro-5-(cyclopropylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-[(2-methoxyethyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-[(3-hydroxypropyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-[(2-hydroxyethyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(dimethylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-2-pyridin-3-ylacetamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-(piperidin-1-ylmethyl)benzamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-(pyrrolidin-1-ylmethyl)benzamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-{[(2-methoxyethyl)(methyl)amino]methyl}benzamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-methylnicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-[(3-hydroxypropyl)amino]nicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-[(2-furylmethyl)amino]nicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide 1-oxide;   N-[5-(isopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-2-pyridin-3-ylacetamide trihydrochloride;   N-[5-[(1-ethylpropyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(isopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide 1-oxide;   N-[5-[(3-hydroxycyclohexyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide formic acid;   N-{7-chloro-5-[(3-hydroxycyclohexyl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide formic acid;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-[(dimethylamino)methyl]benzamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-[(2-oxopyrrolidin-1-yl)methyl]benzamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-pyrrolidin-1-ylnicotinamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-methylnicotinamide;   N-[5-{[(1R,2S)-2-(hydroxymethyl)cyclohexyl]amino}-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide hydrochloride;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-[(4-hydroxypiperidin-1-yl)methyl]benzamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-(pyrrolidin-1-ylmethyl)benzamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-(4-hydroxypiperidin-1-yl)nicotinamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-piperazin-1-ylnicotinamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-(dimethylamino)nicotinamide;   N-[6-bromo-5-(cyclopentylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-morpholin-4-ylnicotinamide;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-morpholin-4-ylnicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-(dimethylamino)nicotinamide;   tert-butyl 4-[5-({[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}carbonyl)pyridin-2-yl]piperazine-1-carboxylate;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-[(4-hydroxypiperidin-1-yl)methyl]benz amide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-(4-fluoropiperidin-1-yl)nicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-(1H-pyrazol-1-yl)nicotinamide;   tert-butyl 4-[5-({[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino}carbonyl)pyridin-2-yl]piperazine-1-carboxylate;   N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-[(3-hydroxypropyl)amino]nicotinamide;   N-[5-(isopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-(morpholin-4-ylmethyl)nicotinamide;   N-[5-[(pyrrolidin-3-ylmethyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-(piperazin-1-ylmethyl)benzamide;   N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-[(4-formylpiperazin-1-yl)methyl]benz amide;   N-[5-(piperidin-3-ylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(sec-butylamino)-7-chloro[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-[(2-methoxyethyl)(methyl)amino]nicotinamide;   N-[5-(sec-butylamino)-7-chloro[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-[(3-hydroxypropyl)amino]nicotinamide;   N-[5-(sec-butylamino)-7-chloro[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-morpholin-4-ylnicotinamide;   N-[5-(sec-butylamino)-7-chloro[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-{[(2-methoxyethyl)(methyl)amino]methyl}benzamide;   N-[5-(sec-butylamino)-7-chloro[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-methylnicotinamide;   N-[7-chloro-5-(isopropylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-[(3-isopropoxyphenyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-[(3-fluoro-4-methoxyphenyl)amino]-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-{[3-(benzyloxy)phenyl]amino}-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(sec-butylamino)-7-chloro[1,2,4]triazolo[1,5-a]pyridin-2-yl]-4-(morpholin-4-ylmethyl)benzamide;   N-[5-(isopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-6-methylnicotinamide;   6-chloro-N-[5-(isopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   6-[(2-aminoethyl)amino]-N-[5-(isopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N-[5-(sec-butylamino)-7-methyl[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide; or   N-[5-(isopropylamino)-7-methyl[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide.   
     
     
         7 . A triazolopyridine intermediate compound selected from:
 5-bromo[1,2,4]triazolo[1,5-a]pyridin-2-amine;   5-chloro[1,2,4]triazolo[1,5-a]pyridin-2-amine;   5-chloro-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-amine;   N 5 -cyclohexyl[1,2,4]triazolo[1,5-a]pyridine-2,5-diamine;   N 5 -cycloheptyl[1,2,4]triazolo[1,5-a]pyridine-2,5-diamine;   5-(cyclohexyloxy)[1,2,4]triazolo[1,5-a]pyridin-2-amine;   [1,2,4]triazolo[1,5-a]quinolin-2-amine;   6-bromo-N 5 -cyclohexyl[1,2,4]triazolo[1,5-a]pyridine-2,5-diamine;   N 5 -isopropyl-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridine-2,5-diamine;   N-(5-bromo[1,2,4]triazolo[1,5-a]pyridin-2-yl)nicotinamide;   N-(5-chloro[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzamide;   N-[5-chloro-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   4-(chloromethyl)-N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]benzamide;   N-(5,7-dichloro[1,2,4]triazolo[1,5-a]pyridin-2-yl)nicotinamide;   6-chloro-N-[5-(cyclohexylamino)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide;   N 5 -cyclopropyl-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridine-2,5-diamine;   5-chloro-7-methyl[1,2,4]triazolo[1,5-a]pyridin-2-amine; or   N-(5-chloro-7-methyl[1,2,4]triazolo[1,5-a]pyridin-2-yl)nicotinamide.   
     
     
         8 . A pharmaceutical composition containing at least one triazolopyridine amide compound according to  claim 1  and a pharmaceutically acceptable carrier, diluent or excipient. 
     
     
         9 . A pharmaceutical composition containing at least one triazolopyridine amide compound according to  claim 3  and a pharmaceutically acceptable carrier, diluent or excipient. 
     
     
         10 . A pharmaceutical composition containing at least one triazolopyridine amide compound according to  claim 6  and a pharmaceutically acceptable carrier, diluent or excipient.